

Lymph node yield variability after radical cystectomy: the effect of pathological processing and microscopic examination

Kassem Faraj, MD¹, Nathanael Judge, BS, Yu-Hui H. Chang, MPH, PhD, Gail Blodgett, BS³, Melissa L Stanton, MD⁴, Mark D Tyson, MD¹ ¹Division of Urology, ²Division of Biostatistics, ³Division of Patient Collaboration, ⁴Division of Pathology Mayo Clinic, Phoenix, AZ

Background

- Pelvic lymph node dissection during cystectomy has been used to • determine adequate surgical quality and assist in accurately staging patients
- Known causes for variations in lymph node count can include the level of dissection, surgical skill, patient anatomy, gross pathological processing, and pathological interpretation
- The relationship between the pathology assistant (PA), who performs the gross processing of lymph nodes, and lymph node yield with RC has not been described

Objectives

To test the hypothesis that lymph node yield will vary by PA in patients undergoing RC with PLND

Methods

- This retrospective study reviewed all patients who underwent RC with urinary diversion and PLND at our institution between January 1, 2007 and January 1, 2018
- Patients who underwent RC for benign indications, non-bladder malignancies, or for bladder cancer but did not undergo a lymph node dissection were excluded
- Univariate analysis was performed with Pearson Chi squared test or Fisher's exact test.
- Multivariable linear regression was used to assess whether the mean lymph node counts differed between various groups
- The marginal plots of predicted mean lymph node counts were generated, and the most frequent category for each variable was used to compute the predicted value and the 95% confidence interval around the predicted estimate

Results

- .430 total patients, mean age 72, 81% males
- Median (IQR) lymph node count 15.0 (11.0-21.0)
- 33.3%, 47.9% and 18.8% of patients underwent a lymph node dissection to the level of the external iliac, aortic bifurcation and IMA, respectively
- 74.9% of patients had pure UCC histology
- 53.4% of those with cT2+ disease received neoadjuvant chemotherapy

Table 1. Univariate analysis

	Median node count (IQR)	P value
Level of dissection		<0.001
External Iliac	12.0 (9.0-18.0)	
Aortic bifurcation	16.0 (12.0-21.0)	
IMA	19.0 (15.0-27.0)	
Clinical Stage		0.002
cTis	13.0 (11.0-20.0)	
сТа	12.0 (9.0-15.0)	
cT1	14.0 (9.0-19.5)	
cT2	16.0 (12.0-21.0)	
cT3	18.0 (13.0-24.0)	
cT4	15.0 (12.0-24.0)	
Surgical approach		<0.001
Robotic	18.0 (14.0-24.0)	
Open	13.0 (9.0-18.0)	
Surgeon		<0.001
1	14.0 (10.0-18.8)	
2	20.0 (15.0-26.0)	
3	12.0 (8.0-15.0)	
4	17.0 (12.5-22.0)	
5	14.0 (9.5-18.5)	
6	15.5 (10.8-22.0)	
Pathologist		0.010
1	12.0 (9.0-19.0)	
2	17.0 (12.0-20.8)	
3	14.0 (11.5-16.5)	
4	13.5 (11.0-19.8)	
5	13.0 (9.8-18.5)	
6	17.0 (11-22)	
Pathology assistant		0.010
1	17 (11.8-22.0)	
2	14 (11.0-20.0)	
3	17.0 (11.0-23.0)	
4	15.0 (11.3-24.5)	
5	13.0 (10.0-15.0)	
6	17.5 (9.0-20.3)	



- Marginal plot illustrating mean adjusted lymph node count using multivariable linear regression for pathology assistant
- On MVA, statistical differences in lymph node remained among surgeons, pathologists, extent of lymph node dissection, clinical stage, but not PA

Discussion/Conclusions

- There was no significant variation in lymph node yield after RC that can be attributed to the individual PA
- At most, the predicted lymph node count varied by almost 4 lymph nodes across 6 different PAs
- There was expected variation in lymph node yield on MVA according to surgeon, extent of lymph node dissection, pathologist, and clinical stage

Limitations

- Retrospective study
- Unmeasured confounders likely present (e.g. patient factors)
- Absence of some covariates in model due to concern of overfitting
- Unable to account for samples submitted in total